Key Takeaways

  • Omega Ophthalmics closed a $7 million Series A financing round to support development, manufacturing scale-up, and clinical planning for the Gemini Refractive Capsule
  • The implant technology is designed to provide a platform for IOL implantation while preserving the capsular bag and potentially allowing future lens exchange
  • Omega has scheduled an FDA pre-submission meeting to obtain feedback on its regulatory pathway and clinical development plans ahead of anticipated US clinical studies

Omega Ophthalmics has closed a $7 million Series A financing round as the company advances development of its Gemini Refractive Capsule, an implant technology designed for use in cataract surgery. Omega also announced that it has scheduled a pre-submission meeting with the FDA to discuss the proposed regulatory pathway and clinical development plans for the Gemini technology.

Omega said the financing was led by a group of "strategically aligned ultra-high-net-worth investors." Proceeds from the financing are expected to support continued product development, intellectual property activities, regulatory work, manufacturing scale-up, and clinical planning as Omega prepares for future FDA studies and potential commercialization.

“We are grateful for the support and confidence of our investors who recognize the potential of the Gemini Refractive Capsule to fundamentally improve cataract surgery,” Rick Ifland, chief executive officer of Omega Ophthalmics, said in the announcement.

The Gemini Refractive Capsule is designed to provide a stable platform for IOL implantation while preserving the capsular bag. According to Omega, the technology is intended to improve long-term refractive stability while maintaining the potential for future lens exchange and incorporation of next-generation ophthalmic technologies.

“The Gemini Refractive Capsule has the potential to address longstanding challenges associated with conventional IOL implantation by providing surgeons with greater flexibility while creating opportunities to improve long-term patient outcomes,” said John Berdahl, MD, of Vance Thompson Vision. “If successful, this technology could significantly expand what's possible in refractive cataract surgery.”

The upcoming FDA pre-submission meeting will provide Omega with an opportunity to receive agency feedback on its proposed regulatory pathway and plans for clinical development.